Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs SanDisk — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while SanDisk trades at $1,328.75 (market cap $202.82B). The key difference: SanDisk is far larger — about 207.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and SanDisk is more actively traded (7,345,106 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SanDisk for 10 Days on average.
| MRVI | SNDK | |
|---|---|---|
Market Cap | $977.37M | $202.82B |
Volume | 2,742,564 | 7,345,106 |
Sector | Health | Technology |
52-Week High | $9.00 | $2.34K |
52-Week Low | $2.83 | $140.16 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $1.08B | $198.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SNDK trades at $1,482.33, down 0.34% amid sector-wide pressure from Chinese competition concerns. The stock shows bearish technical signals with strong analyst support (87.5% buy rating) and a $2,160 consensus price target. Recent earnings beats contrast with current negative profitability, though 2026 projections show dramatic improvement to $11.4B net income. The company maintains strong balance sheet fundamentals with $1.48B cash and manageable debt levels.
SNDK presents a compelling risk-reward opportunity with significant upside potential to analyst targets, though near-term volatility from memory sector headwinds persists. The company's AI memory positioning and projected 2026 profitability growth support long-term bullish thesis, while current technical weakness may offer attractive entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
